Form 4: Athira Pharma SVP of Finance and Accounting Reports Routine Stock Transactions
Insider Transaction Report
Robert Renninger, SVP of Finance and Accounting at Athira Pharma, Inc., reported recent acquisitions of common stock through an employee stock purchase plan and RSU vesting, alongside a sale to cover tax obligations.
Summary
- Robert Renninger, SVP, Finance and Accounting at Athira Pharma, Inc. (ATHA), reported transactions involving the company's common stock.
- On May 19, 2025, Renninger acquired 10,000 shares of common stock at $0.2312 per share through the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan (ESPP). This purchase price was 85% of the closing price on that date.
- On June 30, 2025, 12,359 Restricted Stock Units (RSUs) vested and converted into an equal number of common shares. These RSUs were part of a grant of 37,077 RSUs on October 1, 2024, vesting in three equal tranches.
- On July 1, 2025, Renninger sold 2,897 shares of common stock at a weighted-average price of $0.2935 per share. This sale was non-discretionary and solely to cover tax withholding and remittance obligations related to the RSU vesting.
- Following these transactions, Renninger's direct beneficial ownership of Athira Pharma common stock stands at 109,186 shares.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions, including an ESPP purchase and RSU vesting with a mandatory sell-to-cover, which are neutral events. There is no indication of discretionary selling or significant new buying beyond compensation-related activities.
Positives
- Acquisition of 10,000 shares through the Employee Stock Purchase Plan (ESPP) at a discounted price of $0.2312, indicating participation in employee ownership programs.
- Vesting of 12,359 Restricted Stock Units (RSUs) into common stock, representing a realization of equity compensation.
Negatives
- Sale of 2,897 shares to cover tax withholding obligations, which, while non-discretionary, reduces the reporting person's direct shareholding.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Acquisition of shares through the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan (ESPP).
- Vesting of Restricted Stock Units (RSUs) granted under the Issuer's 2020 Equity Incentive Plan.
- Sale of shares to cover tax withholding obligations pursuant to mandatory "sell to cover" policies maintained by the issuer.
Stakeholder Impact
- Shareholders: The reported transactions provide transparency into insider holdings and compensation practices. The "sell to cover" transaction is a common practice and not indicative of a lack of confidence. The ESPP purchase shows management participation in employee stock ownership.
- Employees: The ESPP and RSU programs demonstrate the company's equity compensation structure for employees, including senior management.
Next Steps
- The remaining one-third of the 37,077 RSUs granted on October 1, 2024, are scheduled to vest on December 31, 2025.
Key Dates
| Date | Description |
|---|---|
| 10/01/2024 | Grant date of 37,077 Restricted Stock Units (RSUs) to Robert Renninger. |
| 11/18/2024 | Start of the Offering Period for the Employee Stock Purchase Plan (ESPP) from which shares were acquired. |
| 12/31/2024 | First vesting date for one-third of the granted RSUs. |
| 03/19/2025 | End of the Purchase Period for the Employee Stock Purchase Plan (ESPP). |
| 05/19/2025 | Acquisition date of 10,000 common shares through the ESPP at $0.2312 per share. |
| 06/30/2025 | Vesting and conversion date of 12,359 Restricted Stock Units (RSUs) into common stock. |
| 07/01/2025 | Date of sale of 2,897 common shares to cover tax withholding obligations. |
| 07/02/2025 | Signature date of the Form 4 filing. |
| 12/31/2025 | Third vesting date for one-third of the granted RSUs. |
Keywords
Athira Pharma, ATHA, Form 4, SEC Filing, Insider Trading, Stock Transactions, Employee Stock Purchase Plan, ESPP, Restricted Stock Units, RSU, Equity Compensation, Sell to Cover, Beneficial Ownership, Robert Renninger
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.